Skip to main content

Grisactin 250 Disease Interactions

There are 3 disease interactions with Grisactin 250 (griseofulvin).

Major

Griseofulvin (applies to Grisactin 250) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of griseofulvin is contraindicated in patients with hepatocellular failure, as animal data has shown that this drug may cause hepatocellular necrosis. The use of griseofulvin has not been adequately studied in patients with liver disease, although it is known that griseofulvin is primarily metabolized by the liver. Therapy with griseofulvin should be administered very cautiously in patients with liver impairment, and the dosing adjusted or discontinued according to clinical response.

References (1)
  1. (2002) "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation
Major

Griseofulvin (applies to Grisactin 250) porphyria

Major Potential Hazard, High plausibility.

The use of griseofulvin is contraindicated in patients with porphyria. Griseofulvin has been shown to cause disturbances in porphyrin metabolism in laboratory animals.

References (1)
  1. (2002) "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation
Moderate

Griseofulvin (applies to Grisactin 250) lupus erythematosus

Moderate Potential Hazard, Moderate plausibility.

The use of griseofulvin has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease. Griseofulvin therapy should be withdrawn in patients experiencing worsening of preexisting lupus until another cause can be identified.

References (4)
  1. Madhok R, Zoma A, Capell H (1985) "Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin." Br Med J (Clin Res Ed), 291, p. 249-50
  2. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K (1989) "Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin." J Am Acad Dermatol, 21, p. 343-6
  3. Miyagawa S, Sakamoto K (1989) "Adverse reaction to griseofulvin in patients with circulating anti-ssa/ro and ssb/la autoantibodies." Am J Med, 87, p. 99-102
  4. (2002) "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation

Switch to consumer interaction data

Grisactin 250 drug interactions

There are 273 drug interactions with Grisactin 250 (griseofulvin).

Grisactin 250 alcohol/food interactions

There is 1 alcohol/food interaction with Grisactin 250 (griseofulvin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer